Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome.
Fiche publication
Date publication
avril 2019
Journal
EBioMedicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr COUTANT Charles, Pr MARCHAL Frédéric
Tous les auteurs :
Scholl S, Popovic M, de la Rochefordiere A, Girard E, Dureau S, Mandic A, Koprivsek K, Samet N, Craina M, Margan M, Samuels S, Zijlmans H, Kenter G, Hillemanns P, Dema S, Dema A, Malenkovic G, Djuran B, Floquet A, Garbay D, Guyon F, Colombo PE, Fabbro M, Kerr C, Ngo C, Lecuru F, Campo ERD, Coutant C, Marchal F, Mesgouez-Nebout N, Fourchotte V, Feron JG, Morice P, Deutsch E, Wimberger P, Classe JM, Gleeson N, von der Leyen H, Minsat M, Dubot C, Gestraud P, Kereszt A, Nagy I, Balint B, Berns E, Jordanova E, Saint-Jorre N, Savignoni A, Servant N, Hupe P, de Koning L, Fumoleau P, Rouzier R, Kamal M
Lien Pubmed
Résumé
There is a lack of information as to which molecular processes, present at diagnosis, favor tumour escape from standard-of-care treatments in cervical cancer (CC). RAIDs consortium (www.raids-fp7.eu), conducted a prospectively monitored trial, [BioRAIDs (NCT02428842)] with the objectives to generate high quality samples and molecular assessments to stratify patient populations and to identify molecular patterns associated with poor outcome.
Mots clés
Bioraids study, Cervical cancers, Epigenetics pathways, PI3KCA, Patient stratification, Prospective database, Reverse phase protein array, Whole exome sequencing
Référence
EBioMedicine. 2019 Apr 2;: